Literature DB >> 1628367

Dose dependence of the cytokinetic and cytotoxic effects of epirubicin in vitro.

D Bartkowiak1, J Hemmer, E Röttinger.   

Abstract

CHO cells were exposed in vitro for 1 h to concentrations of 0.1-20 micrograms/ml of the cytostatic drug epirubicin. Population growth, survival fractions, cell-cycle-phase distribution, and BrdU incorporation were analyzed. A fraction of the cells showed a transitory cytostatic reaction at 1 microgram/ml, and greater than 99% of the cells were killed at 10 micrograms/ml. The survival curve was biphasic with a steep slope at concentrations of up to 5 micrograms/ml. Approximately 0.1% of the cells were resistant to higher concentrations of epirubicin. Bivariate DNA/BrdU flow cytometry revealed that the sensitive cells were blocked and probably killed in the G2M phase of the cell cycle.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1628367     DOI: 10.1007/bf00686310

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  17 in total

1.  Comparative effects of doxorubicin and 4'-epi-doxorubicin on nucleic acid metabolism and cytotoxicity in a human tumor cell line.

Authors:  O Cantoni; P Sestili; F Cattabeni; C Geroni; F Giuliani
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy.

Authors:  F M Torti; M M Bristow; B L Lum; S K Carter; A E Howes; D A Aston; B W Brown; J F Hannigan; F J Meyers; E P Mitchell
Journal:  Cancer Res       Date:  1986-07       Impact factor: 12.701

Review 3.  Mechanism of multidrug resistance.

Authors:  G Bradley; P F Juranka; V Ling
Journal:  Biochim Biophys Acta       Date:  1988-08-03

4.  5-Fluorouracil, epirubicin, and BCNU (FEB) in advanced measurable gastric cancer.

Authors:  M Lopez; M Natali; L Di Lauro; G Tonini; S Carpano; P Vici; E M Conti
Journal:  Am J Clin Oncol       Date:  1990-06       Impact factor: 2.339

5.  Epidoxorubicin plus ifosfamide in advanced and/or metastatic soft-tissue sarcomas.

Authors:  S Toma; T Coialbu; L Biassoni; U Folco; C Gatti; G Canavese; A Giacchero; R Rosso
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Epirubicin weekly in combination chemotherapy with cyclophosphamide and vincristine in untreated small cell lung cancer: a phase II trial.

Authors:  A Kretzschmar; P Drings
Journal:  Onkologie       Date:  1990-04

7.  Effect of adriamycin on the cell kinetics of 13762 rat mammary tumors and implications for therapy.

Authors:  P G Braunschweiger; L M Schiffer
Journal:  Cancer Treat Rep       Date:  1980 Feb-Mar

8.  Comparative metabolism and pharmacokinetics of doxorubicin and 4'-epidoxorubicin in plasma, heart and tumor of tumor-bearing mice.

Authors:  W J van der Vijgh; P A Maessen; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

9.  Rapid in vitro bromodeoxyuridine labeling method for monitoring of therapy response in solid human tumors.

Authors:  J Hemmer
Journal:  Cytometry       Date:  1990

10.  VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer.

Authors:  G Altavilla; V Adamo; E Alafaci; B Buemi; N Caristi; G Condemi; G Toscano
Journal:  Tumori       Date:  1989-04-30
View more
  6 in total

1.  Combined effects of epirubicin and tamoxifen on the cell-cycle phases in estrogen-receptor-negative Ehrlich ascites tumor cells.

Authors:  A Aydiner; M Ridvanogullari; D Anil; E Topuz; R Nurten; R Disci
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

2.  Activation markers and cell proliferation as indicators of toxicity: a flow cytometric approach.

Authors:  A Johannisson; A Thuvander; I L Gadhasson
Journal:  Cell Biol Toxicol       Date:  1995-12       Impact factor: 6.691

Review 3.  Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part II: Oncology, chemotherapy and carcinogenesis.

Authors:  F Dolbeare
Journal:  Histochem J       Date:  1995-12

Review 4.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

5.  In vitro effect of amifostine on haematopoietic progenitors exposed to carboplatin and non-alkylating antineoplastic drugs: haematoprotection acts as a drug-specific progenitor rescue.

Authors:  L Pierelli; G Scambia; A Fattorossi; G Bonanno; A Battaglia; A Perillo; G Menichella; P B Panici; G Leone; S Mancuso
Journal:  Br J Cancer       Date:  1998-10       Impact factor: 7.640

6.  [18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil.

Authors:  S A Suttie; K G M Park; T A D Smith
Journal:  Br J Cancer       Date:  2007-09-11       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.